Biochips:
Progress and Prospects
This
report describes a bright, but perhaps turbulent, future. It provides cutting-edge insights into the
technologies, competition, products, strategies, and trends that executives and
investors need to know about in order to stay current in this dynamic and
highly complex business environment.
The biochips industry
underwent a long incubation period as products were developed, perfected, and
beta tested. A significant array of products, now in the early stages of market
introduction, are joining a world made highly complex by issues like
home-brewing, intellectual property disputes, competing technologies, evolving
business plans, and the entry of large companies into a market previously
dominated by venture-backed start-ups.
The microfluidics segment
of the market saw Caliper introduce its LabChip® line for nucleic acid fragment
separation, in concert with instrumentation and marketing by Agilent. Cepheid
introduced the SmartCycler™ for scaling down and speeding up real-time PCR,
while ACLARA is on the brink of introducing its LabCard™ system for
genotyping. Caliper and ACLARA, which are currently locked in a dramatic patent
litigation showdown, are both providing early access pharmaceutical clients
with microfluidic high-throughput equipment to dramatically reduce the
expenditure of valuable compounds and reagents.
University core
microarray centers continue to spring up like mushrooms, producing home-brew
arrays using methods and protocols refined in Linux-like collaborations. Issues
of large standard arrays versus smaller custom arrays and the economics of
production at smaller lot sizes challenge both established players and new
entrants. A variety of intellectual property disputes add uncertainty as large
players are silently backing licensors.
This report, Biochips:
Progress and Prospects is the thoroughly revised and updated third edition
of its best-selling 1999 report, Biochips: From Technologies to Markets.
This Report will provide you with the critical information needed to build
markets and remain competitive in order to become a leader in the biochips
industry.
Unique Benefits of
this Report Include: